Pub Date : 1951-01-01DOI: 10.1097/00000441-193411000-00052
M. Kaess
1 Britton KE, Granowska M. Tumour identification using radiopharmaceuticals. Clin Radiol 1997;52:731–8. 2 Galloway RJ, Smallridge RC. Imaging in thyroid cancer. Endocrinol Metab Clin N Am 1996;25:93–113. 3 Ryan PJ, Fogelman I. The bone scan: where are we now? Semin Nucl Med 1995;25:76–91. 4 Krasnow AZ, Hellman RS, Timins ME, Collier BD, et al. Diagnostic bone scanning in oncology. Semin Nucl Med 1997;27:107–41. 5 Bares R. Skeletal scintigraphy in breast cancer management. Q J Nucl Med 1998;42:43–8. 6 Front D, Israel O. The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. Semin Nucl Med 1995;25:60–71. 7 Chin BB, Zukerberg BW, Buchpiguel C, Alavi A. Thallium-201 uptake in lung cancer. J Nucl Med 1995;36:1514–9. 8 Conti PS, Lilien DL, Hawley K, Keppler J, et al. PET and {18F}-FDG in oncology: a clinical update. Nucl Med Biol 1996;23: 717–35. 9 Cook GJ, Maisey MN. The current status of clin ica l PET imaging. Clin Radiol 1996;51:603–13. 10 Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996;23:737–43. 11 Waxman AD. The role of (99m)Tc methoxyisobutylisonitrile in imaging breast cancer. Semin Nucl Med 1997;27: 40–54. 12 Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998;46:229–37. 13 Goldenberg DM. Perspectives on oncologic imaging with radiolabeled antibodies. Cancer 1997;80 (Suppl 12): 2431–5. 14 Bader M, Koppenhagen K. Somatostatin receptor scintigraphy in the diagnosis of neuroendocrine gastroenteropancreatic tumors. Rec Result Cancer Res 1996;142: 137–62. 15 Critchley M. Octreotide scanning for carcinoid tumours. Postgrad Med J 1997; 73:399–402. 16 Shapiro B, Sisson JC, Shulkin BL, Gross MD, Zempel S. The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuroendocrine tumors. Q J Nucl Med 1995; 39:(Suppl 1):3–8. 17 Wahl RL. Overview of the current status of PET in breast cancer imaging. Q J Nucl Med 1998;42:1–7. 18 Buscombe JR, Cwikla JB, Thakrar DS, Hilson AJ. Scintigraphic imaging of breast cancer: a review. Nucl Med Commun 1997;18:698–709. 19 Alazraki NP, Eshima D, Eshima LA, Herda SC, et al. Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers. Semin Nucl Med 1997;27:55–67. 20 North JH Jr, Spellman JE. Role of sentinel node biopsy in the management of malignant melanoma. Oncology 1996;10: 1237–42.
{"title":"[Neurology and psychiatry].","authors":"M. Kaess","doi":"10.1097/00000441-193411000-00052","DOIUrl":"https://doi.org/10.1097/00000441-193411000-00052","url":null,"abstract":"1 Britton KE, Granowska M. Tumour identification using radiopharmaceuticals. Clin Radiol 1997;52:731–8. 2 Galloway RJ, Smallridge RC. Imaging in thyroid cancer. Endocrinol Metab Clin N Am 1996;25:93–113. 3 Ryan PJ, Fogelman I. The bone scan: where are we now? Semin Nucl Med 1995;25:76–91. 4 Krasnow AZ, Hellman RS, Timins ME, Collier BD, et al. Diagnostic bone scanning in oncology. Semin Nucl Med 1997;27:107–41. 5 Bares R. Skeletal scintigraphy in breast cancer management. Q J Nucl Med 1998;42:43–8. 6 Front D, Israel O. The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. Semin Nucl Med 1995;25:60–71. 7 Chin BB, Zukerberg BW, Buchpiguel C, Alavi A. Thallium-201 uptake in lung cancer. J Nucl Med 1995;36:1514–9. 8 Conti PS, Lilien DL, Hawley K, Keppler J, et al. PET and {18F}-FDG in oncology: a clinical update. Nucl Med Biol 1996;23: 717–35. 9 Cook GJ, Maisey MN. The current status of clin ica l PET imaging. Clin Radiol 1996;51:603–13. 10 Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996;23:737–43. 11 Waxman AD. The role of (99m)Tc methoxyisobutylisonitrile in imaging breast cancer. Semin Nucl Med 1997;27: 40–54. 12 Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998;46:229–37. 13 Goldenberg DM. Perspectives on oncologic imaging with radiolabeled antibodies. Cancer 1997;80 (Suppl 12): 2431–5. 14 Bader M, Koppenhagen K. Somatostatin receptor scintigraphy in the diagnosis of neuroendocrine gastroenteropancreatic tumors. Rec Result Cancer Res 1996;142: 137–62. 15 Critchley M. Octreotide scanning for carcinoid tumours. Postgrad Med J 1997; 73:399–402. 16 Shapiro B, Sisson JC, Shulkin BL, Gross MD, Zempel S. The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuroendocrine tumors. Q J Nucl Med 1995; 39:(Suppl 1):3–8. 17 Wahl RL. Overview of the current status of PET in breast cancer imaging. Q J Nucl Med 1998;42:1–7. 18 Buscombe JR, Cwikla JB, Thakrar DS, Hilson AJ. Scintigraphic imaging of breast cancer: a review. Nucl Med Commun 1997;18:698–709. 19 Alazraki NP, Eshima D, Eshima LA, Herda SC, et al. Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers. Semin Nucl Med 1997;27:55–67. 20 North JH Jr, Spellman JE. Role of sentinel node biopsy in the management of malignant melanoma. Oncology 1996;10: 1237–42.","PeriodicalId":18963,"journal":{"name":"Munchener medizinische Wochenschrift","volume":"5 1","pages":"1281-5"},"PeriodicalIF":0.0,"publicationDate":"1951-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89706047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}